Korean Circ J.  2010 Mar;40(3):137-140. 10.4070/kcj.2010.40.3.137.

Relationship Between Gallbladder Distension and Lipid Profiles in Kawasaki Disease

• Kim KW
• Kim HY
• Chun JK
• Cha BH
• Namgoong M
• Kwon W
• Lee HY

• KMID: 2094074
• DOI: http://doi.org/10.4070/kcj.2010.40.3.137

Abstract

BACKGROUND AND OBJECTIVES
Kawasaki disease (KD) is an acute systemic vasculitis in children which causes coronary arterial dilatation (CAD) and gallbladder distension (GBD). There is a dearth of investigating the relationship between the severity of KD and GBD with lipid profiles. SUBJECTS AND METHODS: A total of 80 patients with 'complete KD' who were diagnosed from January 2005 to May 2009 was enrolled in this study. Serum cholesterol {total, high density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL-C)}, triglyceride (TG), complete blood count, inflammation markers {erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)} were measured at the time of admission during febrile period. Echocardiography and abdominal sonogram were performed in all patients to determine CAD and gallbladder size. According to GBD, patients with KD were classified as patients with GBD and patients without GBD. Between two groups, demographic and clinical data were analyzed. RESULTS: The serum level of LDL-C was significantly lower in patients with GBD (p=0.03) compared with patients without GBD or febrile control. There was no significant difference in inflammatory indices between patients with GBD and patients without GBD. GBD was not significant risk factor of CAD in this study (odds ratio=2.0, 95% confidence interval=0.82-5.3, p=0.16). CONCLUSION: This is the first study that highlights the relationship between the GBD and lipid metabolism in patients with KD. This study provides clinical insights about potential mechanism underpinning the relationship between the GBD and lipid metabolism.

Keyword

Gallbladder disease; Lipids; Coronary artery disease; Children

MeSH Terms

Blood Cell Count
C-Reactive Protein
Child
Cholesterol
Coronary Artery Disease
Dilatation
Echocardiography
Gallbladder
Gallbladder Diseases
Humans
Inflammation
Lipid Metabolism
Mucocutaneous Lymph Node Syndrome
Risk Factors
Systemic Vasculitis
C-Reactive Protein
Cholesterol

Reference

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967. 16:178–222.

2. Kim DS. Kawasaki disease. Yonsei Med J. 2006. 47:759–772.

3. Falcini F, Cimaz R, Calabri GB, et al. Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. Clin Exp Rheumatol. 2002. 20:421–426.

4. Lee SC, Tchah H, Na SY, Kim HS, Park HJ, Shin MK. Clinical and histopathologic findings on the abnormal liver function complicated with Kawasaki disease. Korean J Pediatr Gastroenterol Nutr. 2000. 3:47–55.

5. Suddleson EA, Reid B, Woolley MM, Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. J Pediatr Surg. 1987. 22:956–959.

6. Bader-Meunier B, Hadchouel M, Fabre M, Arnoud MD, Dommergues JP. Intrahepatic bile duct damage in children with Kawasaki disease. J Pediatr. 1992. 120:750–752.

7. De-Leon-Bojorge B, Zaltzman-Girsevich S, Ortega-Salgado A, Prieto-Patron A, Cordoba-Cordoba R, Yamazaki-Nakashimada M. Thrombotic microangiopathy involving the gallbladder as an unusual manifestation of systemic lupus erythematosus and antiphospholipid syndrome: case report and review of the literature. World J Gastroenterol. 2006. 12:7206–7209.

8. Pamuk ON, Umit H, Unlu E, Koker IH, Cakir N. An increased frequency of gallbladder stones in rheumatoid arthritis patients: factors related to gallbladder stone formation. Clin Exp Rheumatol. 2006. 24:317–320.

9. Mitra A, Singh S, Devidayal , Khullar M. Serum lipids in north Indian children treated for Kawasaki disease. Int Heart J. 2005. 46:811–817.

10. Kim H, Yamaguchi H, Inamo K, Okada T, Harada K. Changes in apolipoproteins during the acute phase of Kawasaki disease. Acta Paediatr Jpn. 1995. 37:672–676.

11. Ginanni Corradini S, Ripani C, Della Guardia P, et al. The human gallbladder increases cholesterol solubility in bile by differential lipid absorption: a study using a new in vitro model of isolated intra-arterially perfused gallbladder. Hepatology. 1998. 28:314–322.

12. Choi SM, Choi JH. Levels of serum HDL-cholesterol and total cholesterol in Kawasaki disease and their significance. Korean Circ J. 1997. 27:1298–1302.

13. Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol. 2004. 43:120–124.

14. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation. 1991. 84:625–631.

15. Chiang AN, Hwang B, Shaw GC, et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta. 1997. 260:15–26.

16. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006. 2:99–106.

17. Cheung YF, Huang GY, Chen SB, et al. Inflammatory gene polymorphisms and susceptibility to Kawasaki disease and its arterial sequelae. Pediatrics. 2008. 122:e608–e614.

18. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol. 2006. 176:6294–6301.

19. Yoo JH, Kwak HJ, Lee MJ, Suh JS, Rhee CS. Sonographic measurements of normal gallbladder sizes in children. J Clin Ultrasound. 2003. 31:80–84.

20. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004. 364:533–544.

21. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984. 2:1055–1058.

22. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986. 315:341–347.

23. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991. 324:1633–1639.

24. Moon SY, Kim NS, Lee HB, Lee H. Comparative study about the therapeutic effect between single and five-day administration of gammaglobulin in Kawasaki disease. Korean Circ J. 1994. 24:77–85.

25. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995. 96:1057–1061.

26. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004. 110:2747–2771.

27. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJ. Familial hypercholesterolemia in children. Curr Opin Lipidol. 2004. 15:405–411.

28. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J. 2008. 72:1583–1587.

29. Lehtonen L, Svedström E, Korvenranta H. The size and contractility of the gallbladder in infants. Pediatr Radiol. 1992. 22:515–518.